KemPharm (KMPH) Given a $9.00 Price Target at Royal Bank of Canada
Several other analysts have also commented on the company. Zacks Investment Research raised KemPharm from a hold rating to a buy rating and set a $4.25 price objective on the stock in a report on Wednesday, November 15th. ValuEngine raised KemPharm from a strong sell rating to a sell rating in a report on Sunday, December 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $8.35.
Shares of KemPharm (NASDAQ:KMPH) traded up $0.06 on Tuesday, reaching $5.70. The company’s stock had a trading volume of 214,837 shares, compared to its average volume of 87,900. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. KemPharm has a one year low of $2.45 and a one year high of $5.75. The firm has a market capitalization of $74.75, a price-to-earnings ratio of -2.16 and a beta of -1.09.
In other news, EVP Daniel L. Cohen purchased 7,500 shares of the stock in a transaction dated Monday, November 27th. The shares were purchased at an average cost of $3.79 per share, with a total value of $28,425.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 22.80% of the company’s stock.
A hedge fund recently raised its stake in KemPharm stock. C WorldWide Group Holding A S lifted its position in KemPharm, Inc. (NASDAQ:KMPH) by 14.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 435,528 shares of the specialty pharmaceutical company’s stock after acquiring an additional 53,829 shares during the period. C WorldWide Group Holding A S owned 2.97% of KemPharm worth $1,611,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 36.04% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/19/kempharm-kmph-given-a-9-00-price-target-at-royal-bank-of-canada.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.